Saturday, August 23, 2025 8/23/2025

Lactate production by tumor associated macrophages promotes tumorigenesis

Award Number: R01CA251677
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 03/01/2021
PERIOD OF PERFORMANCE END DATE: 02/28/2026

Group Awards By:

View Award Description

Lactate production by tumor associated macrophages promotes tumorigenesis - ABSTRACT Tumor-associated macrophages (TAMs) are the most prevalent immune cell in the tumor microenvironment. TAMs adopt an M2-like phenotype that supports angiogenesis, attenuates anti-cancer immune responses, and facilitates metastatic dissemination. Studies in humans and experimental animal models support targeting TAMs for anti-cancer therapy. However, the environmental conditions triggering M2 polarization and molecular mechanisms mediating this process are poorly understood. This knowledge is required to target TAMs therapeutically and to identify patients that would benefit from such therapies. One potential pathway for TAM polarization is via metabolic reprogramming. Previous studies showed that glycolysis supports a pro-inflammatory, anti-tumor M1 phenotype in macrophages, while mitochondrial respiration is required for the M2 phenotype. Our recently published work challenged this paradigm. We showed that treating macrophages with LPS or bacteria (M1 stimuli) induce lactate production which in turn, promotes a late phase switch to an M2-like phenotype. The mechanism underlying this surprising observation involves a novel lactate-induced epigenetic modification (H3 lysine lactylation (Kla)) at promoters of genes associated with the M2-phenotype that directly promotes transcription. Hypoxic conditions, such as those found in tumors, also induce lactate production by macrophages. In preliminary work, we show that hypoxia induces expression of M2-like macrophage genes, and these genes are marked by Kla at their promoters. We further show that TAMs isolated from tumors with high hypoxia have elevated levels of histone Kla and M2-like proteins in comparison to TAMs tumors with low hypoxia. Finally, we show that inhibiting endogenous lactate production by TAMs (via myeloid cell specific deletion of Ldha) attenuates the M2-like phenotype of TAMs, lessens tumor growth, and increases CD8+ effector T cells in tumors with high hypoxia, but not in tumors with low hypoxia. Based on these studies, we hypothesize that a lactate-Kla pathway induces the M2-like phenotype of TAMs during hypoxia and promotes tumor growth by suppressing adaptive immunity. To test this hypothesis, we propose three aims: (1) determine the contribution of TAM lactate production to its M2-like phenotype during hypoxia, (2) dissect mechanisms by which lactate production by TAMs promotes tumorigenesis, and (3) determine the contribution of histone lactyltransferases to histone Kla and M2-like phenotype and function of macrophages. By integrating human studies with mechanistic animal, cell-based, epigenetic, and biochemical studies, our proposed work seeks to delineate the mechanisms that promote M2- like TAMs and their effects on tumor development. Delineating these mechanisms may identify potential molecular targets for TAM-based therapeutics that improve anti-tumor immunity and reduce tumorigenesis.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $498,206 )
2025	2025	UNIVERSITY OF CHICAGO	5801 S ELLIS AVE	CHICAGO	IL	60637	COOK	USA	Cancer Biology Research	000	5	2/14/2025	NON-COMPETING CONTINUATION	$498,206
														Subtotal = $498,206

Issue Date FY: 2024 ( Subtotal = $525,883 )
2024	2024	UNIVERSITY OF CHICAGO	5801 S ELLIS AVE	CHICAGO	IL	60637	COOK	USA	Cancer Biology Research	001	4	4/17/2024	NON-COMPETING CONTINUATION	$27,677
2024	2024	UNIVERSITY OF CHICAGO	5801 S ELLIS AVE	CHICAGO	IL	60637	COOK	USA	Cancer Biology Research	000	4	2/7/2024	NON-COMPETING CONTINUATION	$498,206
														Subtotal = $525,883

Issue Date FY: 2023 ( Subtotal = $553,078 )
2023	2023	UNIVERSITY OF CHICAGO	5801 S ELLIS AVE	CHICAGO	IL	60637	COOK	USA	Cancer Biology Research	000	3	2/20/2023	NON-COMPETING CONTINUATION	$553,078
														Subtotal = $553,078

Issue Date FY: 2022 ( Subtotal = $555,737 )
2022	2022	UNIVERSITY OF CHICAGO, THE	5801 S ELLIS AVE	CHICAGO	IL	60637	COOK	USA	Cancer Biology Research	001	2	6/17/2022	NON-COMPETING CONTINUATION	$45,368
2022	2022	UNIVERSITY OF CHICAGO, THE	5801 S ELLIS AVE	CHICAGO	IL	60637	COOK	USA	Cancer Biology Research	000	2	2/17/2022	NON-COMPETING CONTINUATION	$510,369
														Subtotal = $555,737

Issue Date FY: 2021 ( Subtotal = $568,686 )
2021	2021	UNIVERSITY OF CHICAGO, THE	5801 S ELLIS AVE	CHICAGO	IL	60637	COOK	USA	Cancer Biology Research	000	1	2/12/2021	NEW	$568,686
														Subtotal = $568,686

Grand Total All Awards = $2,701,590

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Lactate production by tumor associated macrophages promotes tumorigenesis

Award Number: R01CA251677

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 03/01/2021

PERIOD OF PERFORMANCE END DATE: 02/28/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer